EMA Backs Continuous Levodopa Infusion for Advanced Parkinson’s Disease

The European Medicines Agency (EMA) has issued a positive opinion for the use of continuous subcutaneous infusion of levodopa for the treatment of advanced Parkinson’s disease. This approval offers a new therapeutic option for patients experiencing significant motor fluctuations despite optimized oral levodopa therapy.

Understanding the Challenges of Advanced Parkinson’s

Parkinson’s disease is a progressive neurological disorder that affects movement. Whereas levodopa remains the gold standard treatment, long-term use can lead to motor complications, including unpredictable “on-off” fluctuations where symptoms are either well-controlled or return. These fluctuations can significantly impact a patient’s quality of life.

How Continuous Levodopa Infusion Works

The approved treatment, Onerji, delivers levodopa directly under the skin via a small pump, providing a more consistent dose of medication throughout the day. This steadier exposure to levodopa aims to reduce motor fluctuations and improve symptom control compared to traditional oral pills. The infusion is designed for patients with advanced Parkinson’s who have poorly controlled motor fluctuations Medscape.

Recent Developments and Approvals

This positive opinion from the EMA’s Committee for Medicinal Products for Human Use (CHMP) follows a similar approval in Scotland in March 2024 for Produodopa, another levodopa-responsive treatment for advanced Parkinson’s Medscape. The EMA’s backing suggests wider availability across Europe is likely.

Managing Infusion Site Reactions

As with any infusion therapy, potential side effects such as reactions at the infusion site can occur. Experts have developed approaches to manage these reactions, ensuring patients can continue benefiting from the treatment Medscape.

Key Takeaways

• Continuous levodopa infusion offers a new treatment option for advanced Parkinson’s disease with motor fluctuations.
• The treatment aims to provide steadier levodopa levels compared to oral medications.
• The EMA’s positive opinion paves the way for wider access to this therapy in Europe.
• Managing potential infusion site reactions is crucial for treatment success.

The approval of continuous levodopa infusion represents a significant step forward in the management of advanced Parkinson’s disease, offering hope for improved symptom control and quality of life for those struggling with motor fluctuations.